A clinical research group at Yale Medical School anticipates beginning a clinical trial in the near future with pheo/para patients to test a drug already approved for use in multiple types of cancer for efficacy in our patient population. If you are interested in learning more about this trial and being pre-screened for potential inclusion […]
[Editor’s Note: This article was written by Alisa Zaita.] On Friday, May 5, 2017, I attended the 6th Focus on Neuroendocrine Tumors at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia. As usual, the topics and presentations were both informative and engaging. The conference was seamlessly co-chaired by Debbie Cohen, MD and […]
Progenics Pharmaceuticals, Inc., announced the achievement of an important milestone that moves their orphan drug AZEDRA® (iobenguane I 131) Injection closer to requesting FDA-approval. AZEDRA is a targeted radiotherapeutic agent being evaluated as an imaging agent at low doses and a cancer-killing therapy at high doses for the treatment of malignant and/or recurrent pheochromocytoma/paraganglioma. Results […]
(The following article was contributed by Attiya Khan.) Today is Rare Disease Day. In December 2016, I was diagnosed with pheochromocytoma (pheo). Pheo is a rare tumor that usually develops in cells of an adrenal gland. I want to let others know what this has been like for me. This is not so others can […]
The Pheo Para Troopers are being represented in Washington, DC for Rare Disease Week. Share your story with us at #pheopara and #RareDiseaseDay on Facebook and Twitter. Let’s join together and raise awareness! Read this new article from Trooper Attiya Khan – thank you for sharing your story!